Search results
Showing 106 to 120 of 963 results for death
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.
ID NG61/1 Question Preferred place of care and place of death:- When planning and managing end of life care, what factors help children
This indicator covers infant Mortality. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.
Show all sections
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease. It aims to reduce death and disability by improving the quality of emergency and urgent care.
Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.
Endoscopic submucosal dissection knives for the removal of gastrointestinal lesions
In development Reference number: GID-HTE10072 Expected publication date: TBC
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.